RT Journal Article
SR Electronic
T1 Management of latent <em>Mycobacterium tuberculosis</em> infection: WHO guidelines for low tuberculosis burden countries
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1563
OP 1576
DO 10.1183/13993003.01245-2015
VO 46
IS 6
A1 Haileyesus Getahun
A1 Alberto Matteelli
A1 Ibrahim Abubakar
A1 Mohamed Abdel Aziz
A1 Annabel Baddeley
A1 Draurio Barreira
A1 Saskia Den Boon
A1 Susana Marta Borroto Gutierrez
A1 Judith Bruchfeld
A1 Erlina Burhan
A1 Solange Cavalcante
A1 Rolando Cedillos
A1 Richard Chaisson
A1 Cynthia Bin-Eng Chee
A1 Lucy Chesire
A1 Elizabeth Corbett
A1 Masoud Dara
A1 Justin Denholm
A1 Gerard de Vries
A1 Dennis Falzon
A1 Nathan Ford
A1 Margaret Gale-Rowe
A1 Chris Gilpin
A1 Enrico Girardi
A1 Un-Yeong Go
A1 Darshini Govindasamy
A1 Alison D. Grant
A1 Malgorzata Grzemska
A1 Ross Harris
A1 C. Robert Horsburgh, Jr
A1 Asker Ismayilov
A1 Ernesto Jaramillo
A1 Sandra Kik
A1 Katharina Kranzer
A1 Christian Lienhardt
A1 Philip LoBue
A1 Knut Lönnroth
A1 Guy Marks
A1 Dick Menzies
A1 Giovanni Battista Migliori
A1 Davide Mosca
A1 Ya Diul Mukadi
A1 Alwyn Mwinga
A1 Lisa Nelson
A1 Nobuyuki Nishikiori
A1 Anouk Oordt-Speets
A1 Molebogeng Xheedha Rangaka
A1 Andreas Reis
A1 Lisa Rotz
A1 Andreas Sandgren
A1 Monica Sañé Schepisi
A1 Holger J. Schünemann
A1 Surender Kumar Sharma
A1 Giovanni Sotgiu
A1 Helen R. Stagg
A1 Timothy R. Sterling
A1 Tamara Tayeb
A1 Mukund Uplekar
A1 Marieke J. van der Werf
A1 Wim Vandevelde
A1 Femke van Kessel
A1 Anna van't Hoog
A1 Jay K. Varma
A1 Natalia Vezhnina
A1 Constantia Voniatis
A1 Marije Vonk Noordegraaf-Schouten
A1 Diana Weil
A1 Karin Weyer
A1 Robert John Wilkinson
A1 Takashi Yoshiyama
A1 Jean Pierre Zellweger
A1 Mario Raviglione
YR 2015
UL http://erj.ersjournals.com/content/46/6/1563.abstract
AB Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses to previously acquired Mycobacterium tuberculosis infection without clinical evidence of active tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization for a public health approach to the management of LTBI in high risk individuals in countries with high or middle upper income and TB incidence of &lt;100 per 100 000 per year. The guidelines strongly recommend systematic testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients preparing for organ or haematological transplantation, and patients with silicosis. In prisoners, healthcare workers, immigrants from high TB burden countries, homeless persons and illicit drug users, systematic testing and treatment of LTBI is conditionally recommended, according to TB epidemiology and resource availability. Either commercial interferon-gamma release assays or Mantoux tuberculin skin testing could be used to test for LTBI. Chest radiography should be performed before LTBI treatment to rule out active TB disease. Recommended treatment regimens for LTBI include: 6 or 9 month isoniazid; 12 week rifapentine plus isoniazid; 3–4 month isoniazid plus rifampicin; or 3–4 month rifampicin alone.Guidelines on LTBI for low TB incidence countries – essential element of the @WHO #EndTB strategy and TB elimination http://ow.ly/RW8xn